STAAR SURGICAL CO STAA

Healthcare SIC 3851 - Ophthalmic Goods NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Ophthalmic Goods Manufacturing derived Nasdaq

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or "refractive" surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. Unless the context indicates otherwise, "we," "us," the "Company," and "STAAR" refer to STAAR Surgical Company and its consolidated subsidiaries.

Last close 22.61 2026-10-23
Market cap $1.13B 2026-07-03 share count
52-week range 15.59 - 35.87

Valuation FY2025 figures against the last close

P/S4.7x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.62

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $239.4M$313.9M$322.4M$239.4M$230.5M$163.5M$150.2M$22.9M$22.3M$23.3M
Cost of revenue $57.0M$74.3M$69.8M$61.0M$51.8M$45.1M$38.2M$32.4M$26.3M$24.1M
Gross profit $182.4M$239.6M$252.7M$223.4M$178.6M$118.4M$112.0M$91.5M$64.3M$58.4M
R&D $40.1M$45.3M$40.5M$36.0M$33.9M$31.9M$25.3M$22.0M$20.0M$20.7M
SG&A $274.1M$252.2M$224.6M$179.6M$145.3M$111.6M$100.1M$84.9M$67.9M$71.0M
Operating income -$91.7M-$12.6M$28.1M$43.8M$33.3M$6.8M$11.9M$6.6M-$3.6M-$12.7M
Interest expense ————————$112.0K$112.0K
Pre-tax income -$82.3M-$9.1M$33.7M$45.6M$31.3M$8.3M$13.0M$6.6M-$2.3M-$12.4M
Income tax $1.8M$11.2M$12.3M$5.9M$3.8M$2.4M$1.0M$1.7M$157.0K$315.0K
Net income -$80.4M-$20.2M$21.3M$39.7M$27.5M$5.9M$14.0M$5.0M-$2.1M-$12.1M
EPS, basic -1.62-0.410.440.830.580.130.320.12-0.05-0.30
EPS, diluted -1.62-0.410.430.800.560.120.300.11-0.05-0.30
Shares, diluted (wtd. avg.) 49.6M49.1M49.4M49.4M49.5M48.0M46.9M45.3M41.0M40.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $153.2M$144.2M$183.0M$86.5M$199.7M$152.5M$120.0M$104.0M$18.6M$14.1M
Short-term investments $34.4M$86.3M$37.7M$125.2M——————
Receivables $50.1M$77.9M$94.7M$62.4M$43.5M$35.2M$31.0M$25.9M$17.9M$16.3M
Total current assets $311.5M$367.9M$365.3M$311.7M$271.4M$216.4M$174.7M$151.6M$53.9M$49.5M
Property, plant and equipment $73.3M$84.9M$66.8M$50.9M$35.9M$24.0M$17.1M$11.5M$9.8M$11.8M
Goodwill $1.8M$1.8M$1.8M$1.8M$1.8M$1.8M$1.8M$1.8M$1.8M$1.8M
Other intangibles ———$173.0K$218.0K$270.0K$296.0K$243.0K$271.0K$473.0K
Total assets $451.7M$509.5M$488.7M$418.8M$345.8M$257.4M$207.5M$167.3M$67.9M$65.5M
Accounts payable $11.6M$16.7M$13.6M$11.6M$8.7M$7.5M$8.1M$6.5M$6.0M$8.3M
Total current liabilities $68.5M$70.3M$65.0M$51.7M$48.8M$41.2M$34.5M$27.7M$19.1M$21.1M
Total liabilities $107.5M$112.2M$102.7M$82.7M$87.2M$60.2M$47.6M$34.9M$25.0M$27.6M
Retained earnings -$148.0M-$67.6M-$47.4M-$68.7M-$111.4M-$135.9M-$141.8M-$156.3M-$161.2M-$159.1M
Total equity $344.2M$397.3M$386.0M$336.1M$261.6M$197.2M$159.9M$132.4M$42.9M$37.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$34.2M$15.7M$14.6M$35.7M$44.0M$21.0M$25.8M$12.8M$2.9M$1.0M
Depreciation and amortisation $8.3M$6.9M$5.1M$4.5M$3.6M$3.1M$3.7M$2.4M$3.1M$2.7M
Stock-based compensation $30.6M$27.2M$23.5M$20.4M$14.6M$12.1M$10.5M$6.8M$3.2M$8.6M
Capital expenditure $5.8M$23.4M$18.2M$18.1M$13.6M$8.4M$10.1M$2.2M$1.0M$3.2M
Investing cash flow $46.3M-$59.2M$74.3M-$156.4M-$13.6M-$8.4M-$10.2M-$2.2M-$1.0M-$3.2M
Financing cash flow -$4.6M$5.7M$7.4M$8.3M$17.8M$19.6M$149.0K$74.6M$2.4M$3.0M
Buybacks $6.5M—————————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000718937-26-000015.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M 0 200M 400M Revenue, FY2016: 23.3M Gross profit, FY2016: 58.4M Net income, FY2016: -12.1M Revenue, FY2017: 22.3M Gross profit, FY2017: 64.3M Net income, FY2017: -2.1M Revenue, FY2018: 22.9M Gross profit, FY2018: 91.5M Net income, FY2018: 5M Revenue, FY2019: 150.2M Gross profit, FY2019: 112M Net income, FY2019: 14M Revenue, FY2020: 163.5M Gross profit, FY2020: 118.4M Net income, FY2020: 5.9M Revenue, FY2021: 230.5M Gross profit, FY2021: 178.6M Net income, FY2021: 27.5M Revenue, FY2022: 239.4M Gross profit, FY2022: 223.4M Net income, FY2022: 39.7M Revenue, FY2023: 322.4M Gross profit, FY2023: 252.7M Net income, FY2023: 21.3M Revenue, FY2024: 313.9M Gross profit, FY2024: 239.6M Net income, FY2024: -20.2M Revenue, FY2025: 239.4M Gross profit, FY2025: 182.4M Net income, FY2025: -80.4M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $23.3M $22.3M $22.9M $150.2M $163.5M $230.5M $239.4M $322.4M $313.9M $239.4M
Gross profit $58.4M $64.3M $91.5M $112.0M $118.4M $178.6M $223.4M $252.7M $239.6M $182.4M
Net income -$12.1M -$2.1M $5.0M $14.0M $5.9M $27.5M $39.7M $21.3M -$20.2M -$80.4M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3851

TickerCompanyMarket capP/ERevenue growth
COO COOPER COMPANIES, INC. $11.94B 32.7x 5.1%
BLCO Bausch & Lomb Corp $6.24B — 6.5%
WRBY Warby Parker Inc. $3.21B 2,591.0x 13.0%
EYE National Vision Holdings, Inc. $1.48B 50.5x 9.0%
RXST RxSight, Inc. $208.8M — -3.9%
LUCY Innovative Eyewear Inc $7.5M — 62.6%
ALC ALCON INC — — 4.9%